Biocept (BIOC) | Stock Overview & Key Data
Biocept Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $270,540.00 on February 3, 2014
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2023
Annual Income Flow
2022
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Biocept
BIOC
|
1.14M Micro-cap | N/A | N/A | N/A | N/A | N/A | 0.00% | 0.00% | 0.00% | -100.00% | -90.75% | -90.23% |
|
Thermo Fisher
TMO
|
174.55B Large-cap | 0.87% | 8.07% | 0.79% | -17.74% | -20.05% | 16.53% | -12.65% | -2.72% | 220.94% | 654.32% | 1,231.84% |
|
Danaher
DHR
|
126.39B Large-cap | -1.32% | 11.85% | -5.38% | -20.75% | -21.40% | -10.25% | -15.98% | -20.94% | 174.08% | 416.93% | 738.84% |
|
Atlantic
ATLN
|
134.91M Micro-cap | -25.97% | -59.86% | -86.56% | -62.25% | -72.06% | -75.41% | -96.63% | -99.67% | -99.67% | -99.67% | -99.67% |
|
Aclaris Therapeutics
ACRS
|
600.55M Small-cap | 1.79% | 15.45% | 33.65% | 28.22% | 97.22% | 193.88% | -57.73% | -76.38% | -77.18% | -65.44% | -65.44% |
|
Exagen
XGN
|
64.46M Micro-cap | 8.81% | 25.55% | 44.62% | -34.99% | -24.34% | -34.41% | 43.69% | -70.12% | -72.53% | -72.53% | -72.53% |
Ownership & Short Interest
Calculate Your Biocept Investment Returns
Long-Term Investment Performance Analysis
Biocept stock price in Jul 2016 was $16,740.00, A $1,000.00 lump sum investment in Biocept made 8 years ago would be worth approximately $0.03 today, representing a negative return of -100.00%. This translates to an annualized return (CAGR) of -69.41%.
8 Years 11 Months Investment Scenario (Jul 2016 - Jun 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BIOC's 52-week high and low?
- In the last 52 weeks, Biocept reached a high of $0.49 (on April 1, 2025) and a low of $0.00 (on N/A).
- What is the market cap and P/E ratio for BIOC?
- Curious about Biocept's size and valuation? Its market capitalization stands at 1.14M. When it comes to valuation, the P/E ratio (trailing twelve months) is -0.01, and the forward P/E (looking ahead) is -0.32.
- Does BIOC pay dividends? If so, what's the yield?
- As for dividends, Biocept isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Biocept's main competitors or similar companies to consider before investing?
When looking at Biocept, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Thermo Fisher
TMO174.55B Healthcare Diagnostics & Research 16.53% -12.65% Danaher
DHR126.39B Healthcare Diagnostics & Research -10.25% -15.98% Atlantic
ATLN134.91M Industrials Staffing & Employment Services -75.41% -96.63% Aclaris Therapeutics
ACRS600.55M Healthcare Biotechnology 193.88% -57.73% Exagen
XGN64.46M Healthcare Diagnostics & Research -34.41% 43.69% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Biocept Inc? (e.g., ROE, Debt/Equity)
- To get a sense of Biocept's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -362.16%, the Debt to Equity ratio from the most recent quarter is 39.97, and its Gross Profit Margin stands at -332.94%.
- What is the recent revenue and earnings growth for BIOC?
- Looking at Biocept's growth, its revenue over the trailing twelve months (TTM) was $26M. Compared to the same quarter last year (YoY), quarterly revenue grew by -12.48%, and quarterly earnings saw a YoY growth of N/A.
- How much of BIOC stock is held by insiders and institutions?
- Wondering who owns Biocept stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.